301096 百诚医药
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)4.89410.5288.0898.35818.558
总资产报酬率 ROA (%)3.5408.2436.6336.23311.273
投入资产回报率 ROIC (%)3.8148.9667.0626.63212.862

边际利润分析
销售毛利率 (%)68.75265.52867.37367.26565.813
营业利润率 (%)25.51029.19331.05731.78931.253
息税前利润/营业总收入 (%)25.25426.97724.54632.01331.460
净利润/营业总收入 (%)25.55326.73531.94629.64627.597

收益指标分析
经营活动净收益/利润总额(%)104.531102.44990.73396.33085.081
价值变动净收益/利润总额(%)0.097-0.036-2.081-0.5471.467
营业外收支净额/利润总额(%)0.122-0.4541.185-0.0350.557

偿债能力分析
流动比率 (X)1.8421.9005.5384.7081.964
速动比率 (X)1.6801.7905.3114.6601.934
资产负债率 (%)28.41926.84515.27320.7560.468
带息债务/全部投入资本 (%)20.97815.2123.57012.66434.942
股东权益/带息债务 (%)359.982529.9792,540.417662.769165.420
股东权益/负债合计 (%)251.836272.510554.820381.801113.537
利息保障倍数 (X)-88.002-12.943-3.566135.989978.968

营运能力分析
应收账款周转天数 (天)94.94361.82067.05353.50853.260
存货周转天数 (天)134.66481.71580.74838.88815.595